CY1107323T1 - Αναστολεις πρωτεασωμικης δρασης για διεγepση τριχοφυϊας - Google Patents
Αναστολεις πρωτεασωμικης δρασης για διεγepση τριχοφυϊαςInfo
- Publication number
- CY1107323T1 CY1107323T1 CY20071100174T CY071100174T CY1107323T1 CY 1107323 T1 CY1107323 T1 CY 1107323T1 CY 20071100174 T CY20071100174 T CY 20071100174T CY 071100174 T CY071100174 T CY 071100174T CY 1107323 T1 CY1107323 T1 CY 1107323T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hypothesis
- protective action
- hair
- hair disease
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Birds (AREA)
- General Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
- Surgery (AREA)
Abstract
Συνθέσεις που αναστέλλουν τη δράση του NF-κΒ ή τη δράση του πρωτεασώματος ή ευνοούν τον σχηματισμό οστών και την τριχοφυΐα και είναι κατά συνέπεια χρήσιμες στην θεραπεία της οστεοπόρωσης, της θραύσης ή ατέλειας των οστών, του πρωτογενούς ή δευτερογενούς υπερπαραθυροειδισμού, των περιοδοντικών ασθενειών ή ατελειών, της μεταστατικής ασθένειας των οστών, της οστεολυτικής ασθένειας των οστών, της μεταπλαστικής χειρουργικής, της μεταπροσθετικής χειρουργικής συνδέσμων, και της μετά οδοντικής εμφύτευσης. Επίσης διεγείρουν την παραγωγή τριχοθυλακίων και επομένως είναι χρήσιμες στην διέγερση τριχοφυΐας, συμπεριλαμβανομένης της πυκνότητας μαλλιών, σε οργανισμούς όπου αυτό είναι επιθυμητό.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/113,947 US6462019B1 (en) | 1998-07-10 | 1998-07-10 | Inhibitors of proteasomal activity and production for stimulating bone growth |
EP99933827A EP1096924B1 (en) | 1998-07-10 | 1999-07-09 | Inhibitors of proteasomal activity for stimulating hair growth |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107323T1 true CY1107323T1 (el) | 2012-11-21 |
Family
ID=22352464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100174T CY1107323T1 (el) | 1998-07-10 | 2007-02-09 | Αναστολεις πρωτεασωμικης δρασης για διεγepση τριχοφυϊας |
Country Status (13)
Country | Link |
---|---|
US (3) | US6462019B1 (el) |
EP (1) | EP1096924B1 (el) |
JP (2) | JP2003522107A (el) |
AT (1) | ATE345785T1 (el) |
AU (1) | AU771297B2 (el) |
CA (1) | CA2337988C (el) |
CY (1) | CY1107323T1 (el) |
DE (1) | DE69934120T2 (el) |
DK (1) | DK1096924T3 (el) |
ES (1) | ES2273505T3 (el) |
HK (1) | HK1035870A1 (el) |
PT (1) | PT1096924E (el) |
WO (1) | WO2000002548A2 (el) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6462019B1 (en) * | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6838436B1 (en) * | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6902721B1 (en) | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6492333B1 (en) | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
WO2006089023A2 (en) | 2005-02-16 | 2006-08-24 | The Regents Of The University Of California | Pharmaceutical compositions for treating or preventing bone conditions |
US7884066B2 (en) | 1999-10-05 | 2011-02-08 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
US7052856B2 (en) * | 1999-10-05 | 2006-05-30 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
US20090060988A1 (en) * | 1999-10-05 | 2009-03-05 | Kang Ting | Nell-1 enhanced bone mineralization |
WO2004024893A2 (en) * | 2002-09-13 | 2004-03-25 | The Regents Of The University Of California | Nell-1 enhanced bone mineralization |
US7687462B2 (en) * | 1999-10-05 | 2010-03-30 | The Regents Of The University Of California | Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition |
EP1477180A1 (en) * | 1999-10-20 | 2004-11-17 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone and hair growth |
JP2006517194A (ja) * | 2002-06-06 | 2006-07-20 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム | 骨成長を調節するための方法、組成物および製造物 |
US7041309B2 (en) * | 2002-06-13 | 2006-05-09 | Neuropro Technologies, Inc. | Spinal fusion using an HMG-CoA reductase inhibitor |
CA2492523A1 (en) * | 2002-07-18 | 2004-01-29 | University Of Utah Research Foundation | Novel inhibitors of ubiquitin isopeptidases |
US7029006B2 (en) * | 2002-08-29 | 2006-04-18 | Canon Kabushiki Kaisha | Sheet feeding apparatus and image forming apparatus |
DE602004032107D1 (de) * | 2003-02-07 | 2011-05-19 | Univ California | Nell-peptidexpressionssysteme und knochenbildende aktivität des nell-peptids |
US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
AU2004289229B8 (en) * | 2003-11-05 | 2010-10-07 | Osteoscreen, Inc. | Stimulation of hair growth by Ginkgo biloba flavanoids |
US7691607B2 (en) * | 2004-02-09 | 2010-04-06 | The Regents Of The University Of California | Expression system of NELL peptide |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
US7232818B2 (en) * | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
CN103554222A (zh) | 2004-04-15 | 2014-02-05 | 欧尼斯治疗公司 | 用于抑制蛋白酶体酶的化合物 |
AU2005243140A1 (en) * | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
JP5108509B2 (ja) | 2004-05-10 | 2012-12-26 | プロテオリックス, インコーポレイテッド | 酵素阻害のための化合物 |
FR2870739B1 (fr) * | 2004-05-26 | 2008-05-16 | Oreal | Utilisation du lif en cosmetique et en dermatologie |
US20060167106A1 (en) * | 2004-11-19 | 2006-07-27 | Mei Zhang | Compounds acting at the centrosome |
US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
NZ595196A (en) | 2005-11-09 | 2013-03-28 | Proteolix Inc | Peptide-based compounds for enzyme inhibition |
PL2041158T3 (pl) | 2006-06-19 | 2013-08-30 | Onyx Therapeutics Inc | Peptydowe epoksyketony do hamowania proteasomu |
EP2127681A4 (en) * | 2007-02-16 | 2011-10-12 | Anges Mg Inc | THERAPEUTIC AGENT AGAINST PARODONTAL DISEASES AND ALVEOLAR BONE LOSS THROUGH OPERATION |
US7781650B2 (en) * | 2007-04-30 | 2010-08-24 | Monsanto Technology Llc | Plants and seeds of corn variety CV202909 |
PL2207791T5 (pl) * | 2007-10-04 | 2020-07-27 | Onyx Therapeutics, Inc. | Krystaliczne peptydo- epoksy ketonowe inhibitory proteazy i synteza keto-epoksydów Aminokwasowych |
AP2011005690A0 (en) | 2008-10-21 | 2011-06-30 | Onyx Therapeutics Inc | Combination therapy with peptide epoxyketones. |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
JP5919196B2 (ja) | 2009-11-13 | 2016-05-18 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | 転移抑制のためのペプチドエポキシケトンの使用 |
AU2010341530B2 (en) | 2009-12-22 | 2016-03-10 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
BR112012022060A2 (pt) | 2010-03-01 | 2018-05-08 | Onyx Therapeutics Inc | composto para a inibição de imunoproteassoma |
NZ602872A (en) | 2010-04-07 | 2014-05-30 | Onyx Therapeutics Inc | Crystalline peptide epoxyketone immunoproteasome inhibitor |
US20110281256A1 (en) | 2010-05-17 | 2011-11-17 | Michael Glenn Davis | Systems and Methods of Detecting and Demonstrating Hair Damage Via Evaluation of Protein Fragments |
JP5737756B2 (ja) * | 2011-07-06 | 2015-06-17 | Necプラットフォームズ株式会社 | 通信装置およびパケット廃棄軽減方法 |
WO2013167927A1 (en) * | 2012-05-11 | 2013-11-14 | Biologix Hair Science Ltd. | Formulation and method for treating hair loss |
JP2015524394A (ja) | 2012-07-09 | 2015-08-24 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ |
US10022326B2 (en) * | 2012-07-18 | 2018-07-17 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
SG11201507629XA (en) * | 2013-03-15 | 2015-10-29 | Human Biomolecular Res Inst | Compounds and matrices for use in bone growth and repair |
CN111514128A (zh) * | 2020-04-30 | 2020-08-11 | 广州中医药大学第一附属医院 | 羟基红花黄色素a在制备治疗骨质疏松药物中的应用 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4761471A (en) | 1980-08-04 | 1988-08-02 | The Regents Of The University Of California | Bone morphogenetic protein composition |
JPS60243008A (ja) * | 1984-05-17 | 1985-12-03 | Wakamoto Pharmaceut Co Ltd | 発毛養毛剤 |
JPS6219513A (ja) * | 1985-07-17 | 1987-01-28 | Shiseido Co Ltd | 養毛剤 |
ATE162223T1 (de) | 1989-03-28 | 1998-01-15 | Genetics Inst | Osteoinduktive zusammensetzungen |
WO1992003125A1 (en) | 1990-08-14 | 1992-03-05 | Howmedica Inc | Bone growth stimulator |
JPH0597697A (ja) | 1991-10-02 | 1993-04-20 | Lion Corp | 歯槽骨再生剤 |
WO1993020859A1 (en) | 1992-04-20 | 1993-10-28 | Board Of Regents Of The University Of Washington | Sustained release compositions for delivery of growth factors |
US5962301A (en) * | 1992-06-12 | 1999-10-05 | Massachusetts Institute Of Technology | Relatedness of human interleukin-1β convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor |
JPH08500482A (ja) * | 1992-06-12 | 1996-01-23 | マサチューセッツ インスティテュート オブ テクノロジー | Ced−3及び関連蛋白質のインヒビター |
US5280040A (en) | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
US5965530A (en) | 1993-03-26 | 1999-10-12 | Amgen Inc. | Therapeutic uses of keratinocyte growth factor |
US5840277A (en) | 1993-03-30 | 1998-11-24 | Charlotte Hospital Authority | Treatment of chronic pulmonary inflammation |
DK0724592T3 (da) | 1993-10-21 | 1999-08-30 | Merck & Co Inc | 16-substitueret-4-aza-androstan-5alfa-reduktaseisozym-1-inhibitorer |
US5580854A (en) | 1994-03-04 | 1996-12-03 | Mount Sinai School Of Medicine Of The City University Of New York | Substrate-related peptidyl-aldehyde inhibitors of the proteolytic activity of the multicatalytic proteinase complex |
ATE269102T1 (de) | 1994-03-08 | 2004-07-15 | Osteosa Inc | Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums |
US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6335358B1 (en) * | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
EP0822983A4 (en) * | 1995-04-21 | 2004-12-15 | Merck & Co Inc | apopain |
US5767152A (en) | 1995-05-04 | 1998-06-16 | Nielsen; Thor Bagger | Composition and methods for stimulating hair growth |
US6083690A (en) | 1995-06-02 | 2000-07-04 | Osteoscreen, Inc. | Methods and compositions for identifying osteogenic agents |
US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
EP0850228A1 (en) | 1995-09-01 | 1998-07-01 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
AU706262B2 (en) | 1995-10-23 | 1999-06-10 | Osteoscreen, Inc. | Compositions and methods for treating bone deficit conditions |
FR2741076B1 (fr) * | 1995-11-15 | 1998-01-30 | Rech De Pathologie Appliquee S | Conjugues peptidiques derives des hormones thymiques, leur utilisation a titre de medicament et compositions les contenant |
KR20000022040A (ko) | 1996-06-20 | 2000-04-25 | 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 | 약학적 활성 제제를 제공하기 위한 화합물, 방법 및 그의 용도 |
EP0973513A4 (en) | 1996-10-23 | 2003-03-19 | Zymogenetics Inc | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH BONE DEFICIT |
JP4269015B2 (ja) | 1996-12-13 | 2009-05-27 | オステオスクリーン アイピー, エルエルシー | 骨の成長を刺激する組成物および方法 |
US6495532B1 (en) * | 1997-03-19 | 2002-12-17 | Sky High, Llc | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
DE19716713A1 (de) | 1997-04-21 | 1998-10-22 | Paz Arzneimittelentwicklung | Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz |
JPH11180873A (ja) | 1997-12-22 | 1999-07-06 | Kaken Shoyaku Kk | NF−κB活性阻害剤 |
US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
US6462019B1 (en) * | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6902721B1 (en) * | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6492333B1 (en) * | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
-
1998
- 1998-07-10 US US09/113,947 patent/US6462019B1/en not_active Expired - Lifetime
-
1999
- 1999-07-09 WO PCT/US1999/015533 patent/WO2000002548A2/en active IP Right Grant
- 1999-07-09 AT AT99933827T patent/ATE345785T1/de active
- 1999-07-09 DE DE69934120T patent/DE69934120T2/de not_active Expired - Lifetime
- 1999-07-09 AU AU63109/99A patent/AU771297B2/en not_active Ceased
- 1999-07-09 CA CA2337988A patent/CA2337988C/en not_active Expired - Fee Related
- 1999-07-09 JP JP2000558808A patent/JP2003522107A/ja not_active Withdrawn
- 1999-07-09 ES ES99933827T patent/ES2273505T3/es not_active Expired - Lifetime
- 1999-07-09 DK DK99933827T patent/DK1096924T3/da active
- 1999-07-09 EP EP99933827A patent/EP1096924B1/en not_active Expired - Lifetime
- 1999-07-09 PT PT99933827T patent/PT1096924E/pt unknown
- 1999-07-27 US US09/361,775 patent/US6410512B1/en not_active Expired - Fee Related
-
2001
- 2001-09-19 HK HK01106606A patent/HK1035870A1/xx not_active IP Right Cessation
-
2002
- 2002-01-15 US US10/050,425 patent/US6958220B2/en not_active Expired - Fee Related
-
2005
- 2005-11-15 JP JP2005330878A patent/JP4469780B2/ja not_active Expired - Lifetime
-
2007
- 2007-02-09 CY CY20071100174T patent/CY1107323T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000002548A3 (en) | 2003-04-17 |
DK1096924T3 (da) | 2007-03-26 |
US20020103127A1 (en) | 2002-08-01 |
WO2000002548A2 (en) | 2000-01-20 |
US6958220B2 (en) | 2005-10-25 |
CA2337988A1 (en) | 2000-01-20 |
ATE345785T1 (de) | 2006-12-15 |
US6410512B1 (en) | 2002-06-25 |
JP2003522107A (ja) | 2003-07-22 |
ES2273505T3 (es) | 2007-05-01 |
AU771297B2 (en) | 2004-03-18 |
AU6310999A (en) | 2000-02-01 |
EP1096924A1 (en) | 2001-05-09 |
HK1035870A1 (en) | 2001-12-14 |
DE69934120T2 (de) | 2007-10-11 |
DE69934120D1 (de) | 2007-01-04 |
EP1096924B1 (en) | 2006-11-22 |
PT1096924E (pt) | 2007-02-28 |
US6462019B1 (en) | 2002-10-08 |
JP2006089498A (ja) | 2006-04-06 |
CA2337988C (en) | 2011-04-26 |
JP4469780B2 (ja) | 2010-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107323T1 (el) | Αναστολεις πρωτεασωμικης δρασης για διεγepση τριχοφυϊας | |
EP1021179A4 (en) | METHOD FOR PROMOTING HAIR GROWTH AND DEVELOPING THE HAIR SYSTEM | |
HK1064315A1 (en) | Device stimulating the activity of hair follicles | |
BR0108977A (pt) | Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina | |
DE3280344D1 (de) | Verwendung von retinoiden und minoxidil (2,4-diamino-6-piperidino-pyrimidine-3-oxid) zur verbesserung des wachstums von menschlichem kopfhaar und zur behandlung bestimmter typen von alopecia. | |
CY1108778T1 (el) | Μεθοδος αντιμετωπισης καρκινου του δερματος, χρησιμοποιωντας συνθεσεις οι οποιες περιλαμβανουν εναν αναστολεα του υποδοχεα ενδοθηλινης β | |
CY1111912T1 (el) | Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων | |
DE3765160D1 (de) | Hautbehandlungszusammensetzung. | |
DK1290145T3 (da) | Tredimensional hudmodel | |
ATE258796T1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
BR9507112A (pt) | Preparações higiênicas e cosméticas para evitar e tratar doenças de pele processo para obtenção das mesmas e uso de água esgotada de deutério | |
DE3376524D1 (en) | Skin treatment composition | |
ATE514771T1 (de) | Haartransplantation | |
ATE281167T1 (de) | Verwendung von makroliden zur behandlung von trockenen augen | |
DE69621243D1 (de) | Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls | |
NZ506681A (en) | Disinfecting composition | |
ATE218862T1 (de) | Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen | |
ID24060A (id) | Pengolahan kulit hewan yang ditingkatkan | |
TW200718944A (en) | Screening methods for compounds that affect melanogenesis | |
DK1115375T3 (da) | Anvendelse af mindst ét 10-hydroxy-2-decensyrederivat i et præparat til at fremme hudafstödning | |
HUP9900007A2 (hu) | Készítmény baromfialom kezelésére | |
DE69820911D1 (de) | Verwendung einer Verbindung zur Herstellung eines Medikaments zur Behandlung von Alopecia oder zur Förderung des Haarwuchses bei Tieren | |
ATE358490T1 (de) | Verwendung einer kombination aus einem purin und einem no-donor zur behandlung und prophylaxe sexueller funktionsstörungen | |
ES2152187A1 (es) | Locion estimulante del foliculo piloso. | |
ATE64525T1 (de) | Verwendung von retinoiden und minoxidil (2,4diamino-6-piperidino-pyrimidine-3-oxid) zur verbesserung des wachstums von menschlichem kopfhaar und zur behandlung bestimmter typen von alopecia. |